The concierge medicine model is growing fast in Las Vegas and across the country. Between 2018 and 2023, the number of concierge and direct primary care practice sites grew by over 83%, and the number of clinicians participating in them increased by nearly 78%. But here is the part that rarely gets discussed: not all of these practices deliver the same caliber of care. The quality of a concierge experience depends entirely on who is running it, what they know, and whether they are keeping up with the pace of modern medicine
The Evidence: What Concierge Medicine Can Deliver
When done right, concierge medicine offers measurable advantages. A 2025 systematic review in The American Journal of Medicine found that while large-scale clinical outcome data remain limited, the concierge model is associated with significantly increased patient and physician satisfaction, improved access to preventive health services, and the potential for decreased chronic disease progression and reduced hospital admissions through timely illness management.
The preventive care numbers are particularly striking. One study found that concierge practices achieved a colorectal cancer screening rate of 90.2%, compared to 63.3% in local Medicare Advantage plans and 57.7% to 66.5% nationally. That kind of gap does not happen by accident. It happens because a physician with 300 patients has the bandwidth to track who is overdue for screening and follow up personally, something that is nearly impossible in a panel of 4,000.
The logic behind reduced emergency department utilization is straightforward. When patients can reach their doctor the same day by phone or text, problems get addressed before they escalate. Research on team-based primary care models with enhanced access has demonstrated a 25% reduction in emergency department visits and an 18.6% reduction in hospitalizations among chronically ill patients. The concierge model, with its built-in accessibility, is designed to replicate exactly this kind of proactive engagement.
The Problem: Who Is Actually Running These Practices?
This is where patients need to pay attention. The rapid growth of concierge medicine has attracted a wide range of providers, and not all of them bring the same depth of training or clinical rigor.
One concerning trend is the shift in who staffs these practices. National data show that the share of clinicians in concierge and direct primary care practices who are physicians declined from 67.3% to 59.7% between 2018 and 2023, while the proportion of advanced practice clinicians increased. While nurse practitioners and physician assistants play valuable roles in healthcare delivery, the concierge model was built on the premise of deeper, more complex medical decision-making. Patients paying a premium for personalized care should understand the difference between a practice led by a board-certified physician with years of residency training and one staffed primarily by midlevel providers with significantly less clinical education. The Cochrane review literature suggests that for routine primary care tasks, nurse-led and physician-led care produce broadly similar outcomes. But concierge patients are not paying for routine care. They are paying for the kind of nuanced clinical judgment, diagnostic depth, and complex medication management that comes with medical school, residency, and ongoing board certification.
The other issue is equally important but less discussed: physician currency. A concierge practice led by a physician who graduated from residency decades ago and has not meaningfully updated their clinical knowledge is not delivering premium care. It is delivering outdated care in a nicer office with longer appointments. Medicine evolves rapidly, and patients deserve a doctor whose fund of knowledge reflects where the evidence stands today, not where it stood in 2005.
Why Staying Current Matters More in Concierge Medicine
Consider cardiovascular risk assessment alone. The 2026 ACC/AHA Dyslipidemia Guidelines introduced several major changes that directly affect how primary care physicians should be evaluating and managing their patients. Lipoprotein(a), or Lp(a), is now recommended for measurement in all adults at least once for ASCVD risk assessment, a Class I recommendation. Apolipoprotein B (apoB) testing is now recognized as a reasonable tool for identifying residual cardiovascular risk in patients who have already met their LDL-C goals, particularly those with ASCVD, elevated triglycerides, or type 2 diabetes. The guidelines also introduced the PREVENT-ASCVD equations to replace the older Pooled Cohort Equations for 10-year risk estimation, and elevated coronary artery calcium scoring to a Class I recommendation for risk stratification in intermediate-risk patients.
A concierge physician who is still relying solely on a basic lipid panel and the old risk calculators is missing critical opportunities to identify and manage cardiovascular risk in their patients. Patients are paying for a higher standard of care. They should be getting advanced lipid interpretation, not a recycled approach from a decade ago.
The same principle applies across the board. Patients increasingly seek guidance on hormone optimization therapy, and the evidence base has evolved considerably. The timing hypothesis, transdermal versus oral routes, cardiovascular risk stratification before initiating therapy, and integration with preventive cardiology are all areas where current knowledge matters enormously. A concierge physician who dismisses hormone therapy outright because of outdated impressions from the early Women’s Health Initiative headlines, or conversely prescribes it without proper cardiovascular risk assessment, is not serving their patients well either way.
Peptide therapies represent another frontier where patient demand is outpacing the evidence, and where physician knowledge becomes critical. Compounds like BPC-157 and various growth hormone secretagogues have generated enormous patient interest, largely driven by social media and direct-to-consumer marketing. A 2026 review in The American Journal of Sports Medicine found that while BPC-157 demonstrated potential benefits in preclinical tendon and muscle repair models, human clinical data remain extremely limited, with significant methodological flaws in the available case reports. Most of these peptides lack FDA approval for the conditions they are being marketed for, and their safety profiles in humans are not well established. Patients need a physician who understands this landscape well enough to have an honest, informed conversation about what the evidence actually supports, what remains speculative, and what carries genuine risk. That requires a doctor who is reading the current literature, not one who has never heard of these compounds or, worse, is prescribing them without understanding the limitations of the data.
What Patients Should Demand
Concierge medicine, at its best, represents a return to thoughtful, relationship-driven medical care with the time and access to do it properly. But the model only delivers on that promise when the physician behind it meets a high standard. Patients considering concierge care should look for several things:
A board-certified physician who maintains active certification and continuing medical education. A provider who is familiar with current guidelines, not just in their comfort zone but across the breadth of primary care, including cardiovascular risk assessment, metabolic health, hormone therapy, and emerging therapies. A practice that emphasizes genuine preventive care with personalized screening strategies, not just annual bloodwork on autopilot. And a doctor who is willing to say “the evidence does not support that yet” when it does not, rather than simply offering whatever patients request.
If a concierge physician is not maintaining an adequate fund of knowledge of the latest evidence-based medicine, or is not willing to learn and integrate new developments into their practice, then patients are not getting what they pay for. They are getting a membership fee for the same medicine they could receive in a traditional practice, just with a shorter wait time. That is not concierge medicine. That is a waiting room upgrade.
The physicians who will define the future of concierge medicine in Las Vegas and beyond are those who combine the access and relationship advantages of the model with genuine clinical excellence and intellectual curiosity. Patients deserve both.
Sources
Growth in Number of Practices and Clinicians Participating in Concierge and Direct Primary Care, 2018-23. Health Affairs. 2025. Zhu JM, Marsh T, Polsky D, Huntington A, Song Z.
Maximizing the Value of Concierge Medicine: A Systematic Review of Cost, Access, and Outcomes. The American Journal of Medicine. 2025. Rylands KS, Collins CM, Collins DR.
Collon Cancer Screening in Concierge Practice. Southern Medical Journal. 2017. Nguyen E, Mehta S, Yates SW, Schrader MK, Martin MC.
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2026. Blumenthal RS, Morris PB, Gaudino M, et al.
What to Know About the New Lipid Guidelines. JAMA. 2026. Jennifer Abbasi
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. The Journal of the American Medical Association. 2022. Gartlehner G, Patel SV, Reddy S, et al.
Hormone Therapy for Postmenopausal Women. The New England Journal of Medicine. 2020. Pinkerton JV.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026. Mayfield CK, Bolia IK, Feingold CL, et al.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. Mendias CL, Awan TM.
Association of Team-Based Primary Care With Health Care Utilization and Costs Among Chronically Ill Patients. JAMA Internal Medicine. 2019. Meyers DJ, Chien AT, Nguyen KH, et al.